Blue Cross Launches India’s First-Ever Initiative to Stop Period Pain

#StopThePeriodPain – Don’t take period pain lightly. It is a real medical issue.

New Delhi [India], November 3: In 2020, a single word changed how we looked at health forever: pandemic. COVID-19 became the defining moment of our generation — the first time most of us witnessed a global health crisis unfold in real time. We watched cities lock down, hospitals overflow, and humanity unite to fight an invisible threat. The world’s collective focus was on survival, and we learned how powerful awareness and action could be when everyone comes together for a cause.

But while we’ve been fighting visible pandemics like COVID-19 — and even tackling chronic diseases such as diabetes, hypertension, and heart ailments through national awareness drives — there’s another silent health crisis that has quietly affected millions of women for decades. One that rarely makes headlines, is barely discussed, and has never been treated like the public health issue it truly is.

That crisis is Dysmenorrhea, or what most people simply call period pain.

“Dysmenorrhea, or period pain, affects an estimated 80% of Indian girls and women,”

explains Dr Prabhu Kasture, Director, Medical Services & Pharmacovigilance at Blue Cross Laboratories.

“It is, without a doubt, India’s biggest gynaecological problem. Yet, there have been no national campaigns, no government programs, no large-scale education drives to address it. Because somewhere along the way, menstrual pain stopped being viewed as a health issue. It was normalized — brushed aside with a single dismissive line: ‘It’s just part of being a woman.’”

This cultural conditioning is what the “Stop The Period Pain” campaign aims to change.

We’ve seen campaigns that have made great strides in menstrual hygiene awareness — promoting the use of sanitary napkins and improving access to basic hygiene products.

But #StopThePeriodPain is a step beyond hygiene. It’s the first campaign in India that directly addresses the root cause — the pain itself.

Period

Ashish Shirsat, Sr. Executive Director, Blue Cross Laboratories, explains it perfectly:

“‘Period pain to sabko hota hai’ — this one sentence has normalized menstrual pain for generations. It has placed every kind of pain, from mild discomfort to debilitating cramps, into one bucket. But not all pain is normal. Some of it signals deeper health issues — and ignoring it can have lifelong consequences.”

This normalization has created a dangerous silence around menstrual health.

Girls miss school. Women skip work. Yet most accept this suffering as something they “just have to deal with.”

Pachanan Routray, Sr. Marketing Director, Blue Cross Laboratories, adds:

“We have massive gynaecological problems in India — 80% of girls experience dysmenorrhea. Many of them live with conditions like endometriosis, adenomyosis, or uterine fibroids — all forms of secondary dysmenorrhea — but they go undiagnosed for years because we’ve been taught that period pain is normal. That mindset must change.”

That’s the heart of the message — excessive period pain is not normal.
As the campaign says: “Isko halke mein mat lo.”

The Stop The Period Pain website goes beyond just tools. It’s a complete ecosystem for education and empowerment — featuring personal stories, expert advice, FAQs, and science-backed insights into period pain. It acts as a single, comprehensive guide for girls and women who’ve long suffered in silence, unsure where to turn or what their pain really means.

The message is simple yet powerful: This is not a small problem. Period pain — or dysmenorrhea — is a silent pandemic that affects millions of Indian women and girls, disrupting their education, careers, and quality of life.

Just as the world came together to fight COVID-19, it’s time to unite against this invisible yet deeply personal health crisis — through awareness, education, and empathy.

“Stop The Period Pain” is more than a campaign.
It’s a movement to change how India talks about women’s health — one conversation, one video, one click at a time.

About Blue Cross Laboratories

Founded in 1980 by Chairman Mr. N.H. Israni, Blue Cross Laboratories is one of India’s leading research-based, fast-growing pharmaceutical companies. It provides world-class quality and affordable healthcare products to people across the globe with the aim of improving human life.

Power 250 Technology

DigiSoft Nexus Introduces CollabNexus To Expand Brand & Creators Collaboration Services

Gurugram (Haryana) [India], October 22: CollabNexus by DigiSoft Nexus, has started offering more than just traditional influencer marketing services. The company now provides an all-inclusive collaborative platform that brings together brands, influencers, content creators, and digital talents nationwide. CollabNexus – From Influencer Marketing Services to a Connected Digital Collaboration Ecosystem The introduction of CollabNexus marks […]

Read More
40 plus blood pressure bone density cancer screening Diabetes Health health checkups preventive screening vitamin D

After 40, Your Body Changes Fast: Here’s What Livlong 365 Doctors Say You Must Track Every Year

New Delhi [India], October 21: Forty isn’t a dramatic turning point on its own, but it’s roughly where several slow-moving changes in the body start showing up on paper before they show up as symptoms. Blood pressure creeps, bone density starts to dip, near vision blurs, and nutrient levels quietly fall, all without necessarily feeling […]

Read More
#India Aayush Wellness bone health calcium tablets Health joint health nutraceuticals vitamin D

Aayush Wellness Launches Calcium and Vitamin Supplement, Enters $16.3 Billion Bone & Joint Health Segment

Mumbai (Maharashtra) [India], October 20: Aayush Wellness Limited, an integrated healthcare company, has expanded its nutraceutical portfolio with the launch of Aayush Calcium Vitamin Tablets, a scientifically advanced formulation designed to address India’s calcium and vitamin deficiencies. The launch marks the company’s entry into the bone and joint health segment, estimated at $16.3 billion, and […]

Read More